Not applicableApproved For MarketingNCT03862885
What this trial is testing
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
Who this might be right for
GIST
Blueprint Medicines Corporation
Showing 6 of 0 results